Short answer
Corvus Pharmaceuticals, Inc. (CRVS) filed an 8-K current report with the SEC on August 6, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Q2 and first-half 2026 financial results covered for periods ended June 30, 2026.
Corvus Pharmaceuticals, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q2 and first-half 2026 financial results covered for periods ended June 30, 2026
- Financial position as of June 30, 2026 and business update furnished in Exhibit 99.1
- Investor focus: cash position, operating expenses, and development progress detailed in the accompanying press release
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Corvus Pharmaceuticals, Inc. 8-K filings
Get the next CRVS 8-K as it lands
Follow CRVS for push alerts, or ask the research agent what this filing means.